Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET
31 Outubro 2023 - 8:30AM
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a
rare disease therapeutics company, today announced that it will
host a conference call and live audio webcast on Tuesday, November
7, 2023, at 8:00 a.m. ET, to review its corporate and financial
results for the third quarter of 2023.
The link to audio webcast will be accessible via
the Investor Relations section of the Company’s website,
https://investors.zevra.com/.
To join the meeting by conference call, use the dial-in
information below.
- (800) 343-4849
(U.S.)
- +1 (203) 518-9843
(International)
- Conference ID:
ZVRAQ323
An archive of the webcast will be available for
90 days beginning at approximately 9:00 a.m. ET, on November 7,
2023, at https://investors.zevra.com/.
About Zevra
Therapeutics: Zevra Therapeutics is a rare disease
company melding science, data, and patient need to create
transformational therapies for diseases with limited or no
treatment options. With unique, data-driven clinical, regulatory,
and commercialization strategies, the Company is overcoming complex
drug development challenges to bring much-needed therapies to
patients. With both regulatory and clinical-stage product
candidates, the Company is building its commercial capability to
make new therapies available to the rare disease
community.
Caution Concerning Forward-Looking
Statements:This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include all
statements that do not relate solely to historical or current
facts, including without limitation statements regarding upcoming
events or Zevra’s participation at such events. Forward-looking
statements are based on information currently available to Zevra
and its current plans or expectations. They are subject to several
known and unknown uncertainties, risks, and other important factors
that may cause our actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. These and other important factors are described in
detail in the "Risk Factors" section of Zevra’s Annual Report on
Form 10-K for the year ended December 31, 2022, as updated in
Zevra’s Quarterly Report on Form 10-Q for the quarter ended June
30, 2023, and Zevra’s other filings with the Securities and
Exchange Commission. While we may elect to update such
forward-looking statements at some point in the future, except as
required by law, we disclaim any obligation to do so, even if
subsequent events cause our views to change. Although we believe
the expectations reflected in such forward-looking statements are
reasonable, we cannot assure that such expectations will prove
correct. These forward-looking statements should not be relied upon
as representing our views as of any date after the date of this
press release.
Contacts:
Nichol Ochsner +1 (732)
754-2545 nochsner@zevra.com
Janine Bogris +1 (201)
245-6838 Janine.Bogris@canalecomm.com
Zevra Therapeutics (NASDAQ:ZVRA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Zevra Therapeutics (NASDAQ:ZVRA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024